A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia

Puntos clave

• This study investigates the effectiveness of daratumumab and ibrutinib in treating relapsed and refractory chronic lymphocytic leukemia.
• Phase II clinical trial
• Participants with relapsed/refractory chronic lymphocytic leukemia received daratumumab and ibrutinib
• Outcomes were assessed based on treatment response rates
• Treatment showed improved response rates in patients with relapsed/refractory chronic lymphocytic leukemia
• Combination therapy was well tolerated with manageable side effects
• Further data on efficacy and survival rates is anticipated